Comparative Effectiveness and Obamacare

3 min read
First Published: 
May 2010

President Barack Obama’s political mantra on healthcare reform has comparative effectiveness research forming a substantial part of his strategy.  In 2009’s economic stimulus plan, Congress approved $1.1 billion for comparative effectiveness research.  This has been further bolstered through the Healthcare Reform Bill, passed on 23 March, by the establishment of a dedicated comparative effectiveness research (CER) institute – armed with a $500 million annual budget.

The passing of this legislation has naturally caused a huge amount of debate – with both those supporting and opposing the move clamouring for attention.  Whilst some welcome the introduction of comparative effectiveness as the healthcare cost-saving opportunity that Obama purports, opponents, however, worry about its implications with regards to issues such as quality of care and insurance-coverage decisions.

Whichever side you find yourself on one thing is clear – the implications of Obama’s CER institute will be far-reaching and will have a significant impact.  Comparative effectiveness will be at the heart of major healthcare decisions, whether you are a pharmaceutical supplier, healthcare provider or an insurer – or indeed any other kind of business in the healthcare arena.

So with comparative effectiveness very firmly in the spotlight and destined to stay there for some time, can you honestly say that your business understands the basic concepts that have suddenly become so critical in the US healthcare market place? You may – but do your non-health economist colleagues?  And ask yourself, what could be the implications if they DON’T understand these concepts?

Rx Communications has been active in the field of health economics (HE) and CER for many years, and as such, is regarded as an expert in the field of HE and CER awareness and training.

The latest in our published series is :

Introduction to Comparative Effectiveness


Evidence Based Medicine

This short 60 pp  guide explains these concepts in basic terms, covering the objectives of CER and providing a  rapid read  and understandable reference that you may like to pass to your colleagues.

This booklet is packed with useful definitions, implications and examples. Information is clearly laid out in sections and tables and will give your colleagues a better understanding of your function and the likely implications of CER on your drug and device development activities.

The book also explores other relevant issues in CER such as study methodologies and their application in CER, the role and application of evidence based medicine and how to evaluate comparative effectiveness studies. ‘Comparative Effectiveness and Evidence Based Medicine’ is available to buy online at £15.99 (plus shipping).

The book is available for content and appearance customization incorporating your company’s branding, corporate vocabulary as well as product and device case studies and examples A fully annotated presentation, is also available can be used as a ‘train the trainer’ tool or directly with delegates during training sessions.

For more details about ‘Introduction to Comparative Effectiveness and Evidence Based Medicine’ please do contact Kinza Sutton on +44 1352 706199 or

We'll deliver straight to your inbox

We take your privacy very seriously and will never share your details with other parties.
You're subscribed! We'll send you a welcome email shortly, keep an eye out and if you don't find it perhaps check the (sometimes over-zealous) spam folder.
Oops! Something went wrong while submitting the form.
Kinza Sutton
Share this post

Discover the Power of Communication with Rx

Embark on your medcomms journey with Rx today and experience the difference of working with a world-class medical communications agency.

Child playing in autumn leaves
Copyright Rx Communications Ltd